Screener
United Therapeutics UTHR Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $1.8B+13.2% | $1.28B-32.6% | $1.56B-8.3% | $1.34B-13.8% | $1.59B+17.5% | ||
| $859.1M-41.0% | $874M-38.5% | $1.36B-13.2% | $1.43B-19.5% | $1.46B-9.9% | ||
| $310.3M-18.2% | $312M-3.1% | $350.2M+25.4% | $297.7M-12.9% | $379.3M+30.5% | ||
| $193.8M+14.5% | $178.3M+7.8% | $183.1M+16.0% | $176.5M+20.3% | $169.2M+24.0% | ||
| $3.48B-9.0% | $2.87B-27.1% | $3.7B-4.4% | $3.49B-12.7% | $3.83B+5.7% | ||
| $1.93B+41.7% | $1.84B+41.3% | $1.73B+41.5% | $1.56B+34.5% | $1.36B+24.5% | ||
| $114.1M+2.3% | $115.5M+3.4% | $116.5M+4.1% | $116.7M+4.1% | $111.5M-3.2% | ||
| $7.22B-8.7% | $6.71B-13.3% | $7.88B+7.0% | $7.35B+3.2% | $7.91B+17.6% | ||
| $497.8M+15.2% | $498.3M+35.8% | $488M+41.7% | $468M+28.6% | $432M+32.8% | ||
| $607.8M+15.3% | $599.1M-17.0% | $560.6M-24.0% | $546.3M-37.5% | $527.1M-36.7% | ||
| $819.8M+11.6% | $813.1M-13.2% | $783.8M-14.8% | $760.9M-25.6% | $734.4M-28.4% | ||
| $800K0.0% | $800K0.0% | $800K0.0% | $800K+14.3% | $800K+14.3% | ||
| $9.16B+16.7% | $8.83B+17.1% | $8.56B+18.5% | $8.19B+18.4% | $7.85B+18.8% | ||
| $6.4B-10.8% | $5.9B-13.3% | $7.1B+10.1% | $6.59B+8.0% | $7.17B+25.9% | ||
| $7.22B-8.7% | $6.71B-13.3% | $7.88B+7.0% | $7.35B+3.2% | $7.91B+17.6% |
FAQ
- What are United Therapeutics's total assets?
- United Therapeutics (UTHR) holds $7.2B in total assets, down 8.7% year over year.
- How much cash does United Therapeutics have?
- United Therapeutics holds $1.8B in cash and equivalents.
- Can United Therapeutics cover its short-term obligations?
- Its current ratio is 5.73 — current assets exceed current liabilities.
- Where does United Therapeutics's balance sheet data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
